Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Research analysts at SunTrust Banks lowered their Q3 2017 EPS estimates for shares of Zimmer Biomet Holdings in a report released on Friday. SunTrust Banks analyst B. Nudell now anticipates that the medical equipment provider will post earnings of $1.77 per share for the quarter, down from their previous forecast of $1.96. SunTrust Banks also issued estimates for Zimmer Biomet Holdings’ Q4 2017 earnings at $2.26 EPS and Q2 2018 earnings at $2.17 EPS.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.70% and a net margin of 9.12%. The firm had revenue of $1.95 billion during the quarter, compared to the consensus estimate of $1.95 billion. During the same period last year, the company earned $2.02 EPS. The firm’s revenue for the quarter was up 1.1% compared to the same quarter last year. TRADEMARK VIOLATION NOTICE: “Q3 2017 Earnings Estimate for Zimmer Biomet Holdings, Inc. Issued By SunTrust Banks (NYSE:ZBH)” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2017/08/08/q3-2017-earnings-estimate-for-zimmer-biomet-holdings-inc-issued-by-suntrust-banks-nysezbh.html.

Several other research firms also recently commented on ZBH. Morgan Stanley boosted their price target on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the stock an “overweight” rating in a research note on Monday, July 17th. Stifel Nicolaus restated a “hold” rating and issued a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Piper Jaffray Companies restated a “buy” rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Canaccord Genuity restated a “buy” rating and issued a $141.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet Holdings in a research note on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings currently has an average rating of “Hold” and a consensus price target of $137.76.

Zimmer Biomet Holdings (NYSE ZBH) opened at 117.19 on Monday. The company has a market cap of $23.65 billion, a PE ratio of 33.38 and a beta of 1.20. The company has a 50-day moving average price of $127.65 and a 200 day moving average price of $121.39. Zimmer Biomet Holdings has a 52 week low of $95.63 and a 52 week high of $133.49.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.82%. Zimmer Biomet Holdings’s dividend payout ratio is presently 27.59%.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Sang Yi sold 17,731 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total transaction of $2,208,573.36. The disclosure for this sale can be found here. Corporate insiders own 1.07% of the company’s stock.

Several large investors have recently made changes to their positions in ZBH. Parkside Financial Bank & Trust boosted its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the last quarter. Parallel Advisors LLC boosted its stake in shares of Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock worth $138,000 after buying an additional 199 shares during the last quarter. IHT Wealth Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 256 shares during the last quarter. Sandy Spring Bank boosted its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares during the last quarter. Finally, Ledyard National Bank boosted its stake in shares of Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock worth $157,000 after buying an additional 110 shares during the last quarter. 83.62% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.